Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Q4 FY26 investor presentation: Revenue & Margins
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
The presentation reports a portfolio revenue of approximately EUR 62 million for FY 2025. The provided investor presentation does not contain any specific figures or data regarding EBITDA, operating margin, or profit after tax (PAT) for the quarter, nor any year-on-year changes.
From Gujarat Themis Biosyn Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The presentation reports a portfolio revenue of approximately EUR 62 million for FY 2025.
- There are no specific quarterly revenue, sales, or volume figures disclosed in the presentation.
- No year-on-year change percentages or trends are explicitly mentioned.
- The presentation highlights an expected EPS accretive impact post-acquisition and potential for revenue expansion through multiple levers such as market expansion, lifecycle management, and portfolio optimization.
- It states growth opportunities via access to 55+ countries, expanding presence in Europe, Middle East & Africa, and entry into regulated and high TB-burden markets.
2 more points from Gujarat Themis Biosyn Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gujarat Themis Biosyn Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The acquisition of Sanofi’s Global Anti-TB and Anti-Infective Portfolio is structured as an asset acquisition, including brands, marketing authorizations, dossiers, and inventory, with no transfer of manufacturing facilities or employees (Page 3).
- The approach follows an asset-light growth model with no manufacturing capex required (Page 5).
- Growth is expected to be scalable via brands and distribution, focusing on high-return capital deployment rather than capital-intensive manufacturing expansion (Page 5).
- There is no mention of any new plant, capacity expansion, or capital expenditure amounts or timelines related to physical infrastructure in the presentation.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gujarat Themis Biosyn Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Gujarat Themis Biosyn Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gujarat Themis Biosyn Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹44 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gujarat Themis Biosyn Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Fermenta Biotech Ltd (Q4 FY26)
Q4 FY26 Revenue: ₹547.8 crore, up 14% YoY . Key concall takeaways from Fermenta Biotech Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Amrutanjan Health Care Ltd (Q4 FY26)
149.77 Cr, up 10.60% YoY (Q4 FY25: Rs. Key concall takeaways from Amrutanjan Health Care Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Glenmark Pharmaceuticals Ltd (Q4 FY26)
continued 7-8% of sales reinvestment in R&D fueling innovation and pipeline growth. Key concall takeaways from Glenmark Pharma.'s Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Gujarat Themis Biosyn Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Themis Biosyn Ltd Q4 FY26 results?
The presentation reports a portfolio revenue of approximately EUR 62 million for FY 2025. The provided investor presentation does not contain any specific figures or data regarding EBITDA, operating margin, or profit after tax (PAT) for the quarter, nor any year-on-year changes.
What is Gujarat Themis Biosyn Ltd share price analysis?
Gujarat Themis Biosyn Ltd currently shows a neutral. The stock trades at a P/E of 99.8 with a market cap of ₹4,861 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Themis Biosyn Ltd planning capital expenditure?
The acquisition of Sanofi’s Global Anti-TB and Anti-Infective Portfolio is structured as an asset acquisition, including brands, marketing authorizations, dossiers, and inventory, with no transfer of manufacturing facilities or employees (Page 3).
Keep Gujarat Themis Biosyn Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.